Kisspeptin vs PT-141
Both have been studied in hypoactive sexual desire disorder, but only one cleared the FDA. Kisspeptin remains an early-phase research tool with no approved use.
Short answer
PT-141 has FDA approval and kisspeptin does not, which is the main thing separating them. PT-141 is the one to look at if FDA approval matters to you, though that approval does not cover every use it is marketed for, while kisspeptin is marketed for libido and testosterone.
Kisspeptin
A real hormone atop the reproductive axis with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.
Full Kisspeptin evidence reviewPT-141
Bremelanotide / Vyleesi
FDA-approved as Vyleesi for HSDD in premenopausal women, with phase-3 evidence — but the off-label use in men and at higher doses goes beyond what's proven.
Full PT-141 evidence reviewKisspeptin vs PT-141: head to head
- FDA status / approved use
Kisspeptin
Not approved by any regulator; sold online as an unregulated research productPT-141
FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only- Marketed for
Kisspeptin
Libido, testosteronePT-141
Libido, sexual dysfunction- Outcome areas
Kisspeptin
Sexual health / libido; Testosterone / male hormonesPT-141
Sexual health / libido- Evidence grade
Kisspeptin
Clinical dataPT-141
FDA-approved- How it works
Kisspeptin
Acts on the KISS1 receptor to trigger GnRH, then LH, FSH and testosteronePT-141
Activates melanocortin receptors in the brain involved in sexual desire- Route and dosing
Kisspeptin
Studied as short intravenous infusions; sold online for self-injectionPT-141
On-demand subcutaneous injection before sexual activity, not daily- Headline human result
Kisspeptin
IV kisspeptin-10 raised testosterone and LH in men with type 2 diabetes and mild hypogonadismPT-141
Desire rose 0.35 points and distress fell 0.33 points vs placebo in the phase 3 RECONNECT trials of 1,267 women- Strongest evidence
Kisspeptin
Thurston, JAMA Netw Open 2022Kisspeptin evidence reviewPubMed 36287566PT-141
RECONNECT phase 3, Obstet Gynecol 2019PT-141 evidence reviewPubMed 31599840- Key safety signal
Kisspeptin
No established dose and no long-term safety record for repeated self-injectionPT-141
Nausea is common; transient blood-pressure rise; possible lasting skin darkening- How it is obtained
Kisspeptin
Sold gray-market as a research chemical; no approved or legitimately compounded human productPT-141
Prescribed and dispensed by compounding pharmacies; legality varies by compound
| Kisspeptin | PT-141 | |
|---|---|---|
| FDA status / approved use | Not approved by any regulator; sold online as an unregulated research product | FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only |
| Marketed for | Libido, testosterone | Libido, sexual dysfunction |
| Outcome areas | Sexual health / libido; Testosterone / male hormones | Sexual health / libido |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Acts on the KISS1 receptor to trigger GnRH, then LH, FSH and testosterone | Activates melanocortin receptors in the brain involved in sexual desire |
| Route and dosing | Studied as short intravenous infusions; sold online for self-injection | On-demand subcutaneous injection before sexual activity, not daily |
| Headline human result | IV kisspeptin-10 raised testosterone and LH in men with type 2 diabetes and mild hypogonadism | Desire rose 0.35 points and distress fell 0.33 points vs placebo in the phase 3 RECONNECT trials of 1,267 women |
| Strongest evidence | Thurston, JAMA Netw Open 2022Kisspeptin evidence reviewPubMed 36287566 | RECONNECT phase 3, Obstet Gynecol 2019PT-141 evidence reviewPubMed 31599840 |
| Key safety signal | No established dose and no long-term safety record for repeated self-injection | Nausea is common; transient blood-pressure rise; possible lasting skin darkening |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Prescribed and dispensed by compounding pharmacies; legality varies by compound |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
PT-141 (bremelanotide) is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women, on two placebo-controlled phase 3 trials, with a documented side-effect profile led by nausea plus a transient blood-pressure rise. Kisspeptin has genuine academic human research, including LH-stimulation studies in men and Imperial College brain-imaging work, and a 2022 randomized trial in women with hypoactive sexual desire disorder that measured sexual-response brain activity, but no regulator has approved it and there is no established dose, route, or long-term safety record for the marketed products. The two were studied separately, never against each other.
Kisspeptin fits if
Kisspeptin is worth following as reproductive-axis science, so long as you treat the products sold from it as extrapolations, not a therapy.
PT-141 fits if
PT-141 is the only one of the pair with an approved use, and only for premenopausal women with acquired, generalized HSDD.
Kisspeptin vs PT-141: common questions
- Is PT-141 FDA-approved but kisspeptin not?
- Yes. PT-141 is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only. Kisspeptin is not approved by any regulator; sold online as an unregulated research product.
- Which has stronger human evidence, kisspeptin or PT-141?
- PT-141. It has approval-level evidence (key source: RECONNECT phase 3, Obstet Gynecol 2019), while kisspeptin has human clinical data (key source: Thurston, JAMA Netw Open 2022).
- What are the main safety concerns with kisspeptin and PT-141?
- Kisspeptin has no established dose and no long-term safety record for repeated self-injection. With PT-141, nausea is common; transient blood-pressure rise; possible lasting skin darkening.
Key studies behind each
Kisspeptin
- Seminara SB, Messager S, Chatzidaki EE, et al. (2003). The GPR54 gene as a regulator of puberty. N Engl J Med. PubMed 14573733
- George JT, Veldhuis JD, Roseweir AK, et al. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. PubMed 21632807
- George JT, Millar RP, Anderson RA. (2013). Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf). PubMed 23153270
- Comninos AN, Wall MB, Demetriou L, et al. (2017). Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. PubMed 28112678
PT-141
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. PubMed 31599840
- Yuan XC, Tao YX. (2022). Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. PubMed 36291616
- Simon JA, Kingsberg SA, Portman D, et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. PubMed 31599847
- Spielmans GI. (2021). Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women. J Sex Res. PubMed 33678061
The full evidence reviews
- Kisspeptin: real reproductive-axis science, unproven as a sold therapy
A genuine human hormone atop the testosterone axis, with serious early human research — but the marketed libido and T-booster products are off-label extrapolations at unestablished doses.
Updated August 2026
- PT-141 (bremelanotide): the evidence on a peptide that is actually FDA-approved
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.
Updated August 2026